Month: April 2021

Kinepolis remains financially solid despite prolonged closures and looks forward to reopening cinemas Regulatory release 29 April 2021, 7 a.m. Business update Q1 2021 attached.AttachmentEN Business Update Q1 2021_FINAL

Saint-Herblain (France), April 29, 2021 – Valneva SE (the “Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced its intention to issue and sell, subject to market and other conditions, 7,082,762 of its ordinary shares in a global offering to specified categories of investors comprised of (i) an initial public offering of American Depositary Shares (“ADSs”), each representing two ordinary shares, in the United States (the “U.S. Offering”) and (ii) a concurrent private placement of ordinary shares in certain jurisdictions outside of the United States (the “European Private Placement” and, together with the U.S. Offering, the “Global Offering”). The Company intends to grant the underwriters for the Global...

PRESS RELASE _ NEXANS: HEAD START TO THE YEAR Quarterly sales growth setting robust basis for the year Final steps to “New Nexans” 2019-2021 Transformation PlanSHIFT transformation program structural tailwind across all operationsUniquely placed to build on United States Offshore Wind momentumLaying groundwork of Nexans strategic ambition to Electrify the FutureStandard1 sales of 1,503 million euros in first quarter 2021, representing organic growth2 of +1.4% year-on-year and +5.8% sequentially Current sales land at 1,756 million euros, up +15.2% alongside copper price inflation Topline recovery reflecting healthy backlog across all businesses – notably in Subsea High-Voltage with an adjusted backlog at 1.5 billion euros3, continued customer selectivity for further value growth and pricing increase in line with first sequence of raw...

A conference call will be held today at 14:00 CEST, 13:00 BST, 08:00 EDT. Details are at the end of this statement.Revenue from contracts with customers of CHF 15.0 million Operating result of CHF -53.1 million (2019: CHF –10.4 million) and net result of CHF –67.7 million (2019: CHF –19.0 million) Cash and cash equivalents of CHF 12.4 million as of December 31, 2020 Refreshed clinical and operational strategy as the basis for future growth Strong progress in advancing lead compound vamorolone towards regulatory submission for Duchenne muscular dystrophy (DMD)Pratteln, Switzerland, April 29, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces the Company’s audited financial results for 2020 and reports on progress in advancing its lead compound for the treatment of Duchenne muscular dystrophy (DMD), vamorolone,...

Oslo, 29 April 2021 The Board of Directors of Thin Film Electronics ASA (“Thinfilm”) approved the annual report and the annual financial statements for 2020 on 28 April 2021. The financial statements are consistent with the preliminary report disclosed on 24 February 2021. The auditor’s report contains an emphasis of matter paragraph regarding going concern. The Board does not propose a dividend. The annual report and financial statements for 2020 are enclosed to this announcement and are also available at the Company’s website www.thinfilmsystems.com Contact:Ståle Bjørnstad – Investor RelationsE-mail: stale.bjornstad@thinfilmsystems.comPhone: +47 99 16 76 72 Kevin Barber – Chief Executive OfficerE-mail: kevin.barber@thinfilmsystems.com This information is subject to the disclosure requirements pursuant...

The Nomination Committee of SalMar ASA states that Atle Eide has announced that he will not apply for re-election as Chairman of the Board of the company. In its search for new candidates, the Nomination Committee has emphasized the interests of the shareholder community and the company’s need for competence, experience and capacity. – After a thorough assessment, the committee has come to a recommendation where Leif Inge Nordhammer replaces Atle Eide as chairman of the board, says the chairman of the nomination committee Bjørn Wiggen. Nordhammer was previously CEO in SalMar from 1996 to 2016, with a hiatus from 2011 to 2014. Today he works in his investment company LIN AS and is board member of Kverva AS. He has extensive experience from leadership positions from several companies within aquaculture and has been a part of...

Nokia Corporation Interim report29 April 2021 at 08:00 EET Nokia Corporation Financial Report for Q1 2021 Sales growth in Q1 driving margin increase and strong cash generationStrong start to the year with constant currency net sales up 9% year-on-year, driven by strong growth in Network Infrastructure and solid growth in Mobile Networks; reported net sales increased 3% Enterprise constant currency net sales up 18% year-on-year, as we gained 63 new customers, more than doubling the number we added in Q1 2020; reported net sales increased 14% Comparable gross margin of 38.2% (reported 37.9%), reflecting improvements in Mobile Networks, mainly driven by 5G growth and favorable product and regional mix, and broad improvements across Network Infrastructure Comparable operating margin of 10.9% (reported 8.5%), with improvements in comparable...

Sievi Capital PlcStock exchange release 29 April 2021 at 8:00 am EEST Sievi Capital Plc’s Business Review January–March 2021 Return on equity at a very strong level This is the summary of the Business Review for January–March 2021.The full Business Review is attached to this release and is also available on the company’s website at www.sievicapital.fi. January–March 20211Operating profit was EUR 3.7 (-4.6) million Net profit for the period was EUR 3.5 (-3.7) million Earnings per share (undiluted and diluted) were EUR 0.06 (-0.06) Net asset value per share at the end of the review period was EUR 1.39 (1.14) Return on equity for rolling 12 months was 23.2% (10.7%) Gearing at the end of the review period was -13.2% (-22.7%)Figures in parentheses are figures from the corresponding period in the previous year, unless indicated otherwise....

REGULATED INFORMATION  Ongoing clinical progress across pipeline, including Phase III and IIb clinical trials Multiple new collaborations and partnerships to enhance development, manufacturing and commercialization capabilities Product portfolio broadening from orthopedics into inflammatory conditions, leveraging Bone Therapeutics’ allogeneic MSC platform Three successful funding operations, licensing agreement and optimization of manufacturing assetsManagement to host conference call today at 2pm CEST / 8am EST – details provided belowGosselies, Belgium, 29 April 2021, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces its business update and full year financial results for the year ending 31 December...

STMicroelectronics Reports 2021 First Quarter Financial ResultsQ1 net revenues $3.02 billion; gross margin 39.0%; operating margin 14.6%; net income $364 million Q1 free cash flow(1) $261 million after net capital expenditure payments of $405 million Business outlook at the mid-point: Q2 net revenues of $2.9 billion and gross margin of 39.5%Geneva, April 29, 2021 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, reported U.S. GAAP financial results for the first quarter ended April 3, 2021. This press release also contains non-U.S. GAAP measures (see Appendix for additional information). ST reported first quarter net revenues of $3.02 billion, gross margin of 39.0%, operating margin of 14.6%, and net income of $364 million or $0.39 diluted earnings...